Charlotte McKee

Charlotte is Sionna's, Chief Medical Officer. She has over 20 years of drug development experience, most recently serving as the VP of CF and Alpha-1 Antitrypsin Deficiency Clinical Development at Vertex, where she was instrumental in bringing the CFTR modulators Trikafta/Kaftrio, Symdeko/Symkevi® and Orkambi® to CF patients and expanding indications across the CF portfolio. Prior to Vertex, she was VP and Head of Clinical Development at Infinity Pharmaceuticals after having held positions of increasing responsibility at Tolerx and Wyeth Research (now Pfizer), working across multiple therapeutic areas and modalities.

Prior to her career in the industry, Charlotte was a faculty member in the pulmonary and critical care division at Brigham and Women’s Hospital/Harvard Medical School where she cared for CF patients and specialized in lung transplantation and translational research. She obtained her undergraduate degree from Harvard University and her M.D. from Columbia University Vagelos College of Physicians and Surgeons and completed internal medicine training and pulmonary and critical care fellowship at Johns Hopkins University School of Medicine.